Balances blood sugar levels and helps you lose weight
Is this the breakthrough in the treatment of the common diseases diabetes and obesity? The German scientists who have successfully tested the new drug on humans for the first time speak of excellent effectiveness. The new potent remedy not only lowers blood sugar levels, but also body weight and offers millions of people a new treatment alternative.
A team of researchers from the Leipzig University Medical Center, together with its partners, tested a new drug for the therapy of type 2 diabetes and obesity in a clinical study on humans. According to the results, the preparation shows an excellent effectiveness. The medicine not only lowers the blood sugar level, but at the same time inhibits appetite and thus helps you lose weight. The study results were recently published in the specialist journal "The Lancet".
Two old acquaintances: diabetes and obesity
According to the researchers, in addition to genetic causes, obesity and obesity are the main triggers for type 2 diabetes. "When patients have to inject insulin due to illness or are given insulin-increasing medication, most continue to increase," explains Professor Dr. Michael Stumvoll, director of studies and professor of endocrinology at the University of Leipzig in a press release on the study results.
[GList slug = ”10 tips to lose weight”]
Obesity causes diabetes and vice versa
"We send the patients into a vicious cycle," reports the expert. If people have diabetes because they are overweight, they are given medications that make them gain even more weight. To break this vicious circle, the team developed a drug that lowers blood sugar levels without promoting excess weight. The result is so good that the drug can be used against obesity even without existing diabetes.
A possible magic agent?
The scientists emphasize the peculiarity of the active ingredient, because it not only regulates blood sugar, but also has a satiating effect. The subjects in the study showed improved blood sugar levels and lost weight at the same time. According to the study, a kind of double hormone is responsible for the groundbreaking effectiveness. The injected protein messenger stimulates so-called glucagon receptors that control blood sugar. At the same time, so-called GLP1 receptors are stimulated, which has a beneficial effect on the metabolism in several ways.
Can also be used against obesity
As the researchers report, the metabolism inter alia leads to an increase in the feeling of satiety in the brain. Thus, the drug also has great potential for use against obesity, regardless of the presence of diabetes. The active ingredient is similar to an endogenous hormone called oxyntomodulin. According to the experts, this is one of the satiating intestinal hormones, but has no blood sugar effect.
Phase II successfully completed
"The aim of our investigation was to assess the effectiveness, tolerability and safety of the new preparation," explains Stumvoll. This type of investigation is called a phase II study, in which an active ingredient is tested on patients for the first time. The aim of this phase is to determine the best dosage and to observe possible side effects.
Course of the study
The effectiveness was checked for 112 participants. A control group unwittingly received a placebo. During the test phase, the test subjects were admitted to the hospital and closely monitored. In addition to monitoring various parameters such as blood sugar, heart rate, blood pressure and weight, stress tests were also carried out in which the participants were served certain meals and the hormonal response was observed.
"In this stress test, we were able to determine that the blood sugar with the new preparation did not rise as high as in the placebo group," explains the professor. The insulin reacts faster to fight the increased meal blood sugar. Compared to the placebo group, all subjects were able to improve their blood sugar levels, including those who received the lowest dose. Slight nausea and an increased heart rate were identified as possible side effects.
When will the drug be available?
"Before the drug is approved, it is now important to weigh up the optimal effect and minimal side effects," says Stumvoll. However, he expects market approval soon within the next few years.
The success of the study also strengthens basic research
After the successful study, the Leipzig researchers around Professor Dr. Michael Stumvoll merged with the basic researchers in Munich and founded a new institute. The Leipzig Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG) is expected to transfer further drug candidates from basic research into clinical application in similar studies in the coming years. (vb)